CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 145 enrolled
Drug / intervention
Vehicle +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02479139
NCT02479139Phase 2Completed
CompareCT.gov

Clinical Trial to Evaluate ANT-1207 in the Treatment of Primary Axillary Hyperhidrosis in Adults

Allergan·interventional·Posted Jun 24, 2015·Updated Sep 20, 2017

In Brief

A Phase 2 clinical trial evaluating Vehicle and ANT-1207 for Hyperhidrosis. Completed, enrolled 145 participants across 19 sites.

Detailed Summary

The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 24, 2015
Enrollment StartJun 3, 2015
Primary CompletionFeb 29, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.0 years ago

Interventions

Vehiclebiological

Vehicle for ANT-1207 liniment formulation without active ingredient.

ANT-1207biological

Botulinum toxin Type A topical liniment (ANT-1207).